丙环唑 | 60207-90-1

• 物质功能分类: 化学农药原药 - 杀菌剂 - 其他杀菌剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 丙环唑
• 中文别名: 普克利；1-[2-(2,4-二氯苯基)-4-丙基-1,3-二氧戊环-2-基甲基]-1H-1,2,4-三唑；1-[2-(2,4-二氯苯基)-4-丙基-1,3-二氧戊环-α-甲基]-1-氢-1,2,4-三唑；丙唑灵；必扑尔；1-[2-(2,4-二氯苯基)-4-丙基-1,3-二氧戊环-2-甲基]-1氢-1,2,4-三唑；氧环三宝25EC；敌力脱；1-[2,4-二氯苯基)-4-丙基-1,3-二氧戊环-2-甲基]-1氢-1,2,4-三唑；1-[2,4-二氯苯基)-4-丙基-1,3-二氧戊环-2-甲基]-1氢-1,2,4三唑
• 英文名称: Propiconazole
• 英文别名: 1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole；1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1,2,4-triazole
• CAS: 60207-90-1
• 化学式: C₁₅H₁₇Cl₂N₃O₂
• mdl: MFCD00055299
• 分子量: 342.225
• InChiKey: STJLVHWMYQXCPB-UHFFFAOYSA-N

物化性质

• 熔点：
  <25 °C
• 沸点：
  180°C (0.1 torr)
• 密度：
  1.2700
• 闪点：
  11 °C
• 溶解度：
  DMF: 33 mg/ml,DMF:PBS (pH 7.2)(1:3): 0.16 mg/ml,DMSO: 20 mg/ml,乙醇: 10 mg/ml
• LogP：
  3.7 at 25℃
• 物理描述：
  Yellowish odorless liquid. Non corrosive. Used as a fungicide.
• 颜色/状态：
  Yellowish, viscous liquid
• 气味：
  Practically odorless
• 蒸汽压力：
  1X10-6 mm Hg at 25 °C
• 稳定性/保质期：
  参与丙酮、甲醇、异丙醇等大多数有机溶剂互溶，对光、热、酸、碱都较稳定，对金属无腐蚀性。 对兔眼晴黏膜和皮肤有轻度刺激，但对豚鼠无致敏作用，在试验条件下未见三致现象。
• 分解：
  When heated to decomposition it emits toxic vapors of /nitrogen oxides and hydrogen chloride/.
• 腐蚀性：
  Noncorrosive to metals.
• 解离常数：
  The pKa of the conjugate acid of propiconazole is 1.09.
• 碰撞截面：
  177.88 Ų [M+H]+
• 保留指数：
  2331.3;2305;2343;2312;2299.2;2316.7

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

代谢

经口服给药的(14C)-苯基-丙环唑的代谢在预先给予未标记丙环唑的小鼠中进行研究，随后给予相应剂量水平的单次口服(14C)-苯基-丙环唑。丙环唑的尿代谢物模式显示了明显的性别依赖性。在雄性小鼠中，0-24小时尿液中60%的放射性由一种代谢物代表，这种代谢物在雌性小鼠0-24小时尿液中的比例为30%。通过光谱分析，这种代谢物被鉴定为1-(2,4-二氯苯基)-2-(1H-1,2,4-三唑-1-基)乙醇的葡萄糖醛酸苷。这表明小鼠中的主要代谢途径涉及二氧杂环烷环的裂解。

The metabolism of orally administered (14C)-phenyl propiconazole was studied in mice pretreated with unlabeled propiconazole followed by a single oral dose of (14C)-phenyl propiconazole at a corresponding dose level. The urinary metabolite pattern of propiconazole demonstrated a marked sex dependency. In male mice, 60% of the radioactivity in 0-24 hour urine was represented by one metabolite, this metabolite accounted for 30% in the 0-24 hour urine in female mice. This metabolite was identified by spectroscopy as the glucuronic acid conjugate of 1-(2,4-dichlorophenyl)-2-(1 H-1,2,4-triazol-1-yl) ethanol. This demonstrates that the major metabolic pathway in mice involves dioxolane ring cleavage.

来源:Hazardous Substances Data Bank (HSDB)

代谢

多菌灵的代谢在给予雄性大鼠单次口服剂量31.4 mg/kg的三唑-(3,5-14C-多菌灵)后进行了研究。从第一天尿液和粪便中分离出的代谢物分别代表施用剂量的44.5%和36.2%。发生了广泛的生物转化，导致多种代谢物。酶攻击的主要部位是多菌灵侧链的氧化，通过醇和二醇转化为羧酸和α-羟基羧酸，或者是二氧杂环烷环的断裂。大多数醇类和酚类代谢物以硫酸和葡萄糖醛酸结合物的形式通过肾脏排出。在大鼠中，主要的代谢物是多菌灵的α-羟基羧酸。

The metabolism of propiconazole was investigated in male rats administered a single oral dose of 31.4 mg/kg triazole-(3,5-14C-propiconazole). Metabolites were isolated from first day urine and feces excretion representing 44.5% and 36.2% of the applied dose, respectively. A wide array of biotransformations occurred leading to numerous metabolites. The major site of enzymatic attack oxidation of the propyl side chain leading via alcohols and diols to carboxy acids and alpha-hydroxy carboxy acid or cleavage of the dioxolane ring. The majority of the alcoholic and phenolic metabolites are renally excreted as sulfuric acid and glucuronic acid conjugates. In the rat the main metabolite is the alpha hydroxyl carboxylic acid of propiconazole.

来源:Hazardous Substances Data Bank (HSDB)

代谢

在大鼠中，酶攻击的主要部位是丙基侧链和二氧杂环烷环的裂解，以及2,4-二氯苯基和1,2,4-三唑环的一些攻击。在 mice 中，主要的代谢途径是通过裂解二氧杂环烷环。

/In rats/...the major sites of enzymic attack are the propyl side-chain and the cleavage of the dioxolane ring, together with some attack at the 2,4-dichlorophenyl and 1,2,4-triazole rings. In mice, the major metabolic pathway is via cleavage of the dioxolane ring.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 毒性总结

丙氧咪唑可以降低可能导致多倍体和有丝分裂细胞周期中断的胆固醇水平。它下调PTEN通路，并上调WNT-β-连环蛋白信号通路，这会刺激细胞增殖，可能导致肿瘤发生的结果。

Propiconazole can decrease cholesterol levels that may cause polyploidy and disruption of mitotic cell cycling. It down-regulates the PTEN pathway and up-regulates the WNT-beta-catenin signaling pathway, that would stimulate cell proliferation and may lead to the tumorigenic outcome. (A15329)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌性证据

癌症分类：C组可能的人类致癌物

Cancer Classification: Group C Possible Human Carcinogen

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌物分类

未列在IARC目录中。

Not listed by IARC.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 健康影响

丙环唑可以导致角膜混浊，这种状况在72小时内可逆。在动物长期毒性测试中，在大鼠和小鼠体内发现了良性和恶性的肝脏肿瘤。丙环唑被归类为可能的的人类致癌物。丙环唑也是一种发育毒素，导致了新生幼崽的骨骼畸形。

Propiconazole can cause corneal opacity that is reversible with 72 hours. In animal chronic toxicity tests, the benign and malignant liver tumors were found in rats and mice. Propiconazole is categorized as a possible human carcinogen. Propiconazole is also a developmental toxin that caused skeletal deformations in newborn pups.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 副作用

职业性肝毒素 - 第二性肝毒素：在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒案例。

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

吸收、分配和排泄

经口给予大鼠后，丙硫菌唑迅速吸收，并且通过尿液和粪便迅速且几乎完全排出。组织中的残留物通常较低，没有证据表明丙硫菌唑或其代谢物会在体内积累或滞留。

After oral administration to rats, propiconazole is rapidly absorbed and also rapidly and almost completely eliminated with urine and feces. Residues in tissues were generally low and there was no evidence for accumulation or retention of propiconazole or its metabolites.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

雌雄小鼠被喂食含有5、100和2500 ppm丙硫菌唑的饮食21天，然后口服单剂量(14C)-苯基丙硫菌唑，平均相应剂量水平为(雄性/雌性0.8/1.0、16.8/21.5和434/475 mg/kg体重)。96小时后，尿液排泄占给药剂量的45-81%，且雄性比雌性更高。在粪便中，有22-43%被排出。在最低剂量水平(5 ppm丙硫菌唑)下，血液、肝脏、肾脏、肺脏和剩余尸体中的残留放射性低于0.02 mg/kg丙硫菌唑当量，因此在100和2500 ppm剂量水平下相应更高。在雌性小鼠中的残留物比雄性小鼠高，但在肾脏中雄性显示出更高或相等的值。无论动物剂量水平和性别如何，最高的残留物都发现于肝脏，最高剂量水平下的雄性和雌性分别达到2.3和3.0 mg/kg。

Male and female mice were fed a diet containing 5, 100 and 2500 ppm propiconazole for 21 days, followed by a single oral dose of (14C)-phenyl propiconazole at a mean corresponding dose level (0.8/1.0, 16.8/21.5 and 434/475 mg/kg bw for males/females). Urinary excretion accounted for 45-81% of the administered dose after 96 hours and tended to be higher by males than by females. In the feces 22-43% was excreted. At the lowest dose level (5 ppm propiconazole) the residual radioactivity in blood, liver, kidneys, lungs and in the remaining carcass was below 0.02 mg/kg propiconazole equivalents and accordingly higher at the 100 and 2500 ppm dose level. Residues in female mice were higher than in male mice, except in the kidneys where the males showed higher or equal values. Independent of the dose level and sex of the animals, the highest residues were found in the liver, up to 2.3 and 3.0 mg/kg in males and females of the highest dose level, respectively.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

口服给予大鼠单个剂量的三唑类化合物（3,5-14C）-丙硫菌唑（0.5和25毫克/千克体重）后，在24小时内迅速排泄（74-84%）。6天后，从呼出的空气、粪便和尿液中分别回收了0.04-0.15%、28-46%和53-67%。仅有约0.4%的给药剂量残留在组织中。在肝脏、血液和肾脏中发现了最高的组织残留。尿液中没有未改变的丙硫菌唑排出。在大鼠口服约32毫克/千克体重的三唑类化合物（3,5-14C）-丙硫菌唑或苯基-（U-14C）标记的丙硫菌唑单次剂量后的3天内，超过95%的剂量被排泄。其中，52%在尿液中，43-48%在粪便中。两种化合物的排泄模式相同，尿液中没有发现给药化合物。

Orally administered single doses (0.5 and 25 mg/kg bw) of triazole labelled (3,5-14C)-propiconazole to rats were rapidly excreted within 24 hours (74-84%). After 6 days, 0.04-0.15%, 28-46% and 53-67% had been recovered from expired air, feces and urine respectively. Only about 0.4% of the administered dose remained in the tissues. Highest tissue residues were found in liver, blood and kidneys. No unchanged propiconazole was excreted in the urine. Within 3 days after treatment of male rats with a single oral dose of about 32 mg/kg bw of triazole labelled (3,5-14C)-propiconazole or a phenyl-(U-14C) labelled propiconazole, more than 95% of the dose was excreted. Of this, 52% was found in the urine and 43-48% in the feces. The excretion pattern for both compounds was identical with no administered compound being found in the urine.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

单剂量的三唑-14C-丙环唑（1.0和10.0毫克/千克体重）通过大鼠皮肤给药后被吸收，遵循一级动力学，低剂量和高剂量大鼠的平均半衰期分别为24-31小时。在72小时内，等量的剂量通过尿液和粪便排出。皮肤上的残留放射性活度平均为应用剂量的20%。

Single doses of triazole-14C-propiconazole (1.0 and 10.0 mg/kg bw) applied dermally to rats were absorbed through the skin following first order kinetics with half-lives averaging 24-31 hours for low and high dosed rats, respectively. Equal amounts of the dose were excreted within 72 hours in urine and feces. The amount of residual radioactivity on the skin averaged 20% of the applied dose.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

饲料消耗、产奶量或哺乳期山羊的一般健康在连续10天每天口服5毫克三唑-14C-丙炔氟草胺（相当于饲料中的4.5 ppm）后未受影响。总剂量的89%在最后一次给药后的24小时内被排出（分别以尿液68%和粪便21%的形式）。所有组织的丙炔氟草胺当量含量均小于0.02毫克/千克，除了肝脏（0.096毫克/千克）和肾脏（0.029毫克/千克）。随牛奶分泌的总放射性在第三天达到一个平台，为0.013-0.016毫克/千克，占总剂量的0.18%。

Feed consumption, milk production or the general health of a lactating goat were not affected after the daily oral administration of 5 mg triazole-14C-propiconazole for 10 consecutive days (which would correspond to 4.5 ppm in the feed). Of the total dose, 89% was excreted within 24 hours after the last administration (68% and 21% in urine and feces, respectively). All tissues contained less than 0.02 mg/kg propiconazole equivalents, except liver (0.096 mg/kg) and kidney (0.029 mg/kg). The total radioactivity secreted with the milk reached a plateau at day three of 0.013-0.016 mg/kg, representing 0.18% of the total dose.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  Xn,F,T,N
• 安全说明：
  S16,S36/37,S45,S46,S60,S61,S7
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2934999025
• 危险品运输编号：
  UN3082 9/PG 3
• RTECS号：
  XZ4620000
• 储存条件：
  4℃

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Propiconazole
CAS-No. : 60207-90-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin sensitization (Category 1)
Acute aquatic toxicity (Category 1)
Chronic aquatic toxicity (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. May cause sensitization by skin contact. Very toxic to aquatic organisms, may cause
long-term adverse effects in the aquatic environment.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
H410 Very toxic to aquatic life with long lasting effects.
Precautionary statement(s)
P273 Avoid release to the environment.
P280 Wear protective gloves.
P501 Dispose of contents/ container to an approved waste disposal plant.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R43 May cause sensitization by skin contact.
R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in
the aquatic environment.
S-phrase(s)
S36/37 Wear suitable protective clothing and gloves.
S46 If swallowed, seek medical advice immediately and show this container or
label.
S60 This material and its container must be disposed of as hazardous waste.
S61 Avoid release to the environment. Refer to special instructions/ Safety
data sheets.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C15H17Cl2N3O2
Molecular Weight : 342,22 g/mol
Component Concentration
Propiconazole
CAS-No. 60207-90-1 -
EC-No. 262-104-4
Index-No. 613-205-00-0

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate
personnel to safe areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
Colour: yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 180 °C at 0,129 hPa
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility insoluble
o) Partition coefficient: n- log Pow: 3,5
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
LD50 Oral - rat - 1.517 mg/kg
LC50 Inhalation - rat - 4 h - 1.264 mg/m3
LD50 Dermal - rat - > 4.000 mg/kg
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
May cause allergic skin reaction.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Reproductive toxicity - rat - Oral
Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of
implants). Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus).
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be fatal if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin
May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: XZ4620000

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
Toxicity to fish LC50 - Oncorhynchus mykiss (rainbow trout) - 0,9 - 1,2 mg/l - 96,0 h
Toxicity to daphnia and EC50 - Daphnia magna (Water flea) - 4,8 mg/l - 48 h
other aquatic
invertebrates
Toxicity to algae EC50 - Pseudokirchneriella subcapitata (green algae) - 5 mg/l - 72 h
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
Very toxic to aquatic life.

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3082 IMDG: 3082 IATA: 3082
UN proper shipping name
ADR/RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Propiconazole)
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Propiconazole)
IATA: Environmentally hazardous substance, liquid, n.o.s. (Propiconazole)
Transport hazard class(es)
ADR/RID: 9 IMDG: 9 IATA: 9
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: yes
Special precautions for user
Further information
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and combination
packagings containing inner packagings with Dangerous Goods > 5L for liquids or > 5kg for solids.

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

简介

丙环唑具有广泛杀菌谱、高活性、快速杀菌速度、持久持效期以及强内吸传导性等特点，已成为世界范围内大吨位的三唑类新型广谱性杀菌剂之一。它能有效防治大多数高等真菌引起的病害。

作用

丙环唑属于三唑类杀菌剂，其杀菌特性类似于三唑酮，具有保护和治疗双重功效；具备内吸性能，可通过作物根、茎、叶吸收，并在植物体内向上传导；其抑菌谱较宽广，对子囊菌、担子菌及半知菌中的多种真菌引起的病害有良好防治效果。不过，它对卵菌病害无效。田间持效期约为1个月。

适用作物

丙环唑适用于蔬菜、水稻、小麦、大麦、玉米、人参、香蕉、咖啡、花生、葡萄等多种作物。

毒性

大鼠急性经口LD₅₀为1517毫克/公斤，急性经皮LD₅₀>4000毫克/公斤。对兔眼睛黏膜和皮肤有轻微刺激作用，对豚鼠无致敏性，在试验条件下未发现致癌、致畸或生殖毒性现象。鲤鱼LC₅₀>100毫克/升（96小时），虹鳟鱼783毫克/升。对鸟类实际无毒。

化学性质

丙环唑为淡黄色粘稠液体，沸点180℃/13.32帕，蒸汽压0.133×10^-3帕（20℃），相对密度1.27（20℃），折射率n_D²⁰为1.5468。能与丙酮、甲醇、异丙醇等大多数有机溶剂互溶，在水中溶解度为110毫克/升。对光、热、酸碱稳定，对金属无腐蚀性。

用途

丙环唑是一种具有保护和治疗作用的内吸性三唑类杀菌剂，通过干扰真菌体内的麦角甾醇生物合成而发挥作用，破坏真菌生长繁殖。它适用于防治子囊菌属、担子菌属、半知菌属引起的多种病害，特别是对小麦根腐病、白粉病和锈病、水稻恶苗病以及香蕉叶斑病具有较好的防治效果。

用途实例

1. 防治麦类病害。
2. 防治水稻恶苗病。
3. 防治葡萄白粉病和炭疽病。
4. 防治花生叶斑病。
5. 防治香蕉叶斑病和叶条斑病。

生产方法

制备方法一 将2,4-二氯苯基甲酮溴化，生成2,4-二氯苯基溴甲基酮。再将其与1,2-戊二醇在对甲苯磺酸存在下于甲苯溶剂中反应生成相应的缩酮。然后在二甲基甲酰胺中与1H-1,2,4-三唑反应，制得丙环唑。

制备方法二 （此处省略具体步骤）

制备方法三 （此处省略具体步骤）

类别

农药

毒性分级

中毒

急性毒性

口服：大鼠 LD₅₀: 1517 毫克/公斤

可燃性危险特性

燃烧时产生有毒氮氧化物和氯化物气体。

储运特性

库房应通风、低温干燥，与食品原料分开储运。

灭火剂

干粉、泡沫、砂土。

反应信息

• 作为反应物：
  描述：

  丙环唑 在 异丙基氯化镁 、 sulfur 、 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 以35%的产率得到2-[2-(2,4-dichlorophenyl)-4-propyl-[1,3]dioxolan-2-ylmethyl]-2,4-dihydro[1,2,4]triazole-3-thione
  参考文献：
  名称：

  [EN] A PROCESS USING GRIGNARD REAGENTS
  [FR] PROCÉDÉ UTILISANT DES RÉACTIFS DE GRIGNARD

  摘要：

  本发明涉及一种利用格氏试剂提供含硫代三唑基团化合物的过程。

  公开号：

  WO2011113820A1
• 作为产物：
  描述：

  1,2-戊二醇 在 硫酸 、 三乙胺 作用下， 以 环己烷 、 甲苯 为溶剂， 反应 9.0h， 生成 丙环唑
  参考文献：
  名称：

  一种丙环唑的制备方法

  摘要：

  本发明涉及一种丙环唑的制备方法。为了解决现有技术中涉及高危的溴化反应，会产生大量含溴副产品，单耗和成本高，缩合反应温度高，时间长，溶剂回收困难，废水难处理等明显不足，本发明的制备方法包括使用中间体3与三氮唑或其盐缩合反应生成丙环唑的步骤，所述的中间体3的结构式为：本发明的丙环唑的制备方法避开了传统合成方法中高危险性的溴代反应，避免含溴副产品的产生，并减少环境污染；本发明的丙环唑的制备方法具有优异的原料转化率和收率，产品纯度较高。进一步地，可使用低毒、低成本的反应溶剂代替传统工艺中的高毒DMSO和N,N‑二甲基甲酰胺溶剂，反应更加温和，后处理简化，更加便于操作，且能耗显著降低，更适合工业化生产。

  公开号：

  CN113698393A

文献信息

• [EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
  申请人：GILEAD APOLLO LLC

  公开号：WO2017075056A1

  公开（公告）日：2017-05-04

  The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了化合物I和II，这些化合物可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及它们的组合物和使用方法。
• [EN] BICYCLYL-SUBSTITUTED ISOTHIAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS ISOTHIAZOLINE SUBSTITUÉS PAR UN BICYCLYLE
  申请人：BASF SE

  公开号：WO2014206910A1

  公开（公告）日：2014-12-31

  The present invention relates to bicyclyl-substituted isothiazoline compounds of formula (I) wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及公式（I）中变量如索权和说明中所定义的自行车基取代异噻唑啉化合物。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种通过使用这些化合物来控制无脊椎动物害虫的方法，以及包含所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] AZOLINE COMPOUNDS<br/>[FR] COMPOSÉS AZOLINE
  申请人：BASF SE

  公开号：WO2015128358A1

  公开（公告）日：2015-09-03

  The present invention relates to azoline compounds of formula (I) wherein A, B1, B2, B3, G1, G2, X1, R1, R3a, R3b, Rg1 and Rg2 are as defined in the claims and the description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及式（I）的噁唑啉化合物，其中A、B1、B2、B3、G1、G2、X1、R1、R3a、R3b、Rg1和Rg2如权利要求和描述中所定义。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种利用这些化合物控制无脊椎动物害虫的方法，以及包括所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] SUBSTITUTED QUINAZOLINES AS FUNGICIDES<br/>[FR] QUINAZOLINES SUBSTITUÉES, UTILISÉES EN TANT QUE FONGICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2010136475A1

  公开（公告）日：2010-12-02

  The present invention relates to a compound of formula (I) wherein wherein the substituents have the definitions as defined in claim 1or a salt or a N-oxide thereof, their use and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

  本发明涉及一种具有如下式（I）的化合物，其中取代基具有权利要求1中定义的定义，或其盐或N-氧化物，它们的用途以及用于控制和/或预防植物中微生物感染，特别是真菌感染的方法，以及制备这些化合物的方法。
• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2017157962A1

  公开（公告）日：2017-09-21

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是杀菌剂有用。